NasdaqCM - Delayed Quote • USD
ImmuCell Corporation (ICCC)
At close: April 19 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2021) | Next Qtr. (Jun 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -0.11 | -- | -- |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2021) | Next Qtr. (Jun 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | -- |
| Avg. Estimate | 5.4M | 3.26M | 16.65M | -- |
| Low Estimate | 5.4M | 3.26M | 16.65M | -- |
| High Estimate | 5.4M | 3.26M | 16.65M | -- |
| Year Ago Sales | -- | 2.97M | 15.34M | 16.65M |
| Sales Growth (year/est) | -- | 9.90% | 8.50% | -- |
Earnings History
| CURRENCY IN USD | 6/30/2020 | 9/30/2020 | 12/31/2020 | |
|---|---|---|---|---|
| EPS Est. | -- | -0.1 | -0.08 | -0.04 |
| EPS Actual | -- | -0.11 | -0.04 | 0.03 |
| Difference | -- | -0.01 | 0.04 | 0.07 |
| Surprise % | -- | -10.00% | 50.00% | 175.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2021) | Next Qtr. (Jun 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0.05 | -0.08 | -0.11 | 0 |
| 30 Days Ago | 0.05 | -0.08 | -0.11 | 0 |
| 60 Days Ago | 0.05 | -0.08 | -0.11 | 0 |
| 90 Days Ago | 0.05 | -0.08 | -0.11 | 0 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2021) | Next Qtr. (Jun 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ICCC | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 1.60% |
| Next Qtr. | -- | -- | -- | 10.50% |
| Current Year | -- | -- | -- | 5.20% |
| Next Year | -- | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.22% |
| Past 5 Years (per annum) | 53.90% | -- | -- | -- |
Research Analysis
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Initiated | Aegis Capital: Buy | 7/13/2020 |
Related Tickers
4QK.SG Codexis Inc
2.6120
-0.08%
BRAXF Braxia Scientific Corp.
0.0061
+2.08%
CSBR Champions Oncology, Inc.
5.06
+0.60%
GNTA Genenta Science S.p.A.
3.9010
-0.74%
ANEB Anebulo Pharmaceuticals, Inc.
2.7800
+1.09%
ESLA Estrella Immunopharma, Inc.
1.0700
+4.90%
CDT Conduit Pharmaceuticals Inc.
3.1200
+4.35%
FRES Fresh2 Group Limited
0.3683
+10.07%
INBX Inhibrx, Inc.
34.32
-0.38%
CTCX Carmell Corporation
1.9750
-4.59%